Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Immunother. 2021 Oct 1;44(8):283–291. doi: 10.1097/CJI.0000000000000379

Figure 3: Anti-tumor effects of DFMO/α-PD-1 combination therapy is primarily mediated by CD8+ T cells.

Figure 3:

Mice were SQ seeded with B16/F10 cells as previously and subsequently treated with DFMO/α-PD-1 therapy as previously described. Beginning on day 5 and continuing throughout the experiment, groups of mice were also given twice-weekly intraperitoneal injections of the indicated immune cell depletion antibodies (α-CD4, α-CD8, α-NK1.1, or α-GR1) (n=10/group) twice weekly. (A) Average growth of tumors within each cohort over time. (B) Area of individual tumors 19 days after tumor implantation (the day the first mock tumor reached predetermined end-point criteria). Statistical significance was determined using unpaired Student’s t-test (*=p<0.05, ** = p<0.005).